Subacute cutaneous lupus erythematosus: a decade's perspective

Area of Science:

• Immunodermatology
• Rheumatology
• Autoimmune Diseases

Background:

• Subacute cutaneous lupus erythematosus (SCLE) is a distinct clinical subset of lupus erythematosus.
• Recent worldwide experience supports the viability of the SCLE concept, with characteristic recurrent skin and musculoskeletal manifestations.
• SCLE patients may occasionally develop other autoimmune disorders (e.g., rheumatoid arthritis, Sjögren's syndrome) or experience drug-induced disease flares (e.g., hydrochlorothiazide).

Purpose of the Study:

• To review the current understanding of subacute cutaneous lupus erythematosus (SCLE).
• To identify potential prognostic factors for disease course and risk of systemic lupus erythematosus (SLE) complications.
• To highlight the need for prospective studies to better define SCLE prognosis.

Main Methods:

• Review of published worldwide experience and original reports on SCLE.
• Analysis of preliminary studies suggesting prognostic indicators.
• Discussion of immunogenetic data, including autoantibodies and HLA phenotypes.

Main Results:

• The majority of SCLE patients experience recurrent skin and musculoskeletal symptoms, often with a mild disease course.
• A subset of SCLE patients are at risk for severe, potentially life-threatening systemic lupus erythematosus (SLE) complications.
• Preliminary findings suggest potential prognostic markers including lesional subtype, development of acute cutaneous LE, resistance to antimalarials, leukopenia, high ANA titer, anti-dsDNA antibodies, and rate of systemic disease onset.
• SCLE patients are often immunogenetically homogeneous, frequently possessing anti-Ro autoantibodies and the HLA-DR3 phenotype.

Conclusions:

• Subacute cutaneous lupus erythematosus (SCLE) is a recognized entity with a generally mild course, but with a risk of severe systemic lupus erythematosus (SLE) complications in a small percentage of patients.
• Further research, particularly prospective studies, is needed to identify reliable prognostic features for aggressive disease and favorable outcomes.
• Genetic factors, such as anti-Ro antibodies and HLA-DR3, may play a role in the pathogenesis of SCLE skin lesions.